支气管动脉灌注联合全身化疗治疗晚期非小细胞肺癌

Efficacy of bronchial arterial infusion combined with systemic chemotherapy for patients with advanced non-small cell cancer based on GEMOX regimen

目的观察选择性支气管动脉灌注吉西他滨、奥沙利铂（GEMOX方案）并联合吉西他滨静脉滴注化疗治疗晚期非小细胞肺癌（NSCLC）的疗效和不良反应。方法对38例晚期NSCLC患者第1 d经支气管动脉注入吉西他滨、奥沙利铂,第8 d予吉西他滨静脉滴注化疗,21~28 d为一个周期,完成2~3周期后评价其疗效及不良反应。结果 38例中完全缓解（CR）0例,部分缓解（PR）23例,总有效率60.5%。主要不良反应为骨髓抑制、消化道反应等,不良反应多为Ⅰ~Ⅱ度。结论基于GE-MOX方案的支气管动脉灌注联合全身化疗治疗晚期非小细胞肺癌疗效好、不良反应可耐受。

Objective To evaluate the efficacy and toxicity of bronchial arterial infusion （BAI） combined with systemic chemotherapy based on GEMOX regimen （gemcitabine plus oxaliplatin ） in the treatment of patients withadvanced non-small cell cancer （ NSCLC ）. Methods 38 patients with NSCLC were received GEMOX through the bronchial artery on day 1 and follow by systemic chemotherapy of gemcitabine on day 8 for 2 - 3 cycles, which were repeated every 21 - 28 days. The positive response and adverse effects were assessed. Results In 38 patients, complete response （CR） were obtained in 0 and partial response （PR） in 23 cases, with overall response rate （RR） of 60. 5%. The main toxicity included mild myelosuppression, gastrointestinal effects. Conclusions The combination of BAI and systemic chemotherapy based on GEMOX regimen is highly effective for advanced NSCLC, and causes mild adverse effects.